Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production.
An in vitro model of folate-deficient erythropoiesis has been developed using proerythroblasts isolated from the spleens of Friend virus-infected mice fed an amino acid-based, folate-free diet. Control proerythroblasts were obtained from Friend virus-infected mice fed the same diet plus 2 mg folic acid/kg diet. Our previous studies showed that, after 20 to 32 hours of culture in folate-deficient medium with 4 U/mL of erythropoietin, the folate-deficient proerythroblasts underwent apoptosis, whereas control erythroblasts survived and differentiated into reticulocytes over a period of 48 hours. The addition of folic acid or thymidine to the folate-deficient medium prevented the apoptosis of the folate-deficient erythroblasts, thereby implicating decreased thymidylate synthesis as the main cause of apoptosis in the folate-deficient erythroblasts. In the study reported here, we examined intracellular folate levels, uracil misincorporation into DNA, p53 and p21 proteins, and reticulocyte formation in erythroblasts cultured in folate-deficient or control medium. In all experiments, the folate-deficient erythroblasts cultured in folate-deficient medium gave results that varied significantly from folate-deficient erythroblasts cultured in control medium or control erythroblasts cultured in either folate-deficient or control media. Folate-deficient erythroblasts cultured in folate-deficient medium had marked decreases in all coenzyme forms of folate that persisted throughout culture, increased uracil misincorporation into DNA, persistent accumulations of p53 and p21, and decreased reticulocyte production but increased size of individual reticulocytes. A model of folate-deficient erythropoiesis based on apoptosis of late stage erythroblasts is presented. This model provides explanations for the clinical findings in megaloblastic anemia.
Koury
M J
MJ
Department of Internal Medicine, Vanderbilt University and Veterans Administration Medical Centers, Nashville, TN 37232-6305, USA.
Horne
D W
DW
Brown
Z A
ZA
Pietenpol
J A
JA
Blount
B C
BC
Ames
B N
BN
Hard
R
R
Koury
S T
ST
D000749:Anemia, Megaloblastic / Q000209:etiology / Q000473:pathology*; D000818:Animals; D017209:Apoptosis; D002478:Cells, Cultured; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000096:biosynthesis / Q000737:chemistry; D004249:DNA Damage; D004261:DNA Replication; D004900:Erythroblasts / Q000473:pathology*; D004913:Erythrocytes, Abnormal / Q000473:pathology; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D005492:Folic Acid / Q000494:pharmacology; D005494:Folic Acid Deficiency / Q000150:complications; D006801:Humans; D051379:Mice; D013936:Thymidine / Q000494:pharmacology; D013940:Thymidylate Synthase / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000737:chemistry; D014498:Uracil / Q000378:metabolism
C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53; D014498:Uracil; D005492:Folic Acid; D013940:Thymidylate Synthase; D013936:Thymidine